Navigation Links
Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting

cessful, seek regulatory approval for LX211 in late 2008.”

Dr. Randall Yatscoff, Isotechnika’s President & CEO commented, “We are encouraged by the preclinical data seen to date and we look forward to working with Lux Biosciences to facilitate meeting their clinical development timelines. Uveitis is the third indication that ISA247 (LX211) is currently being developed for. Late-stage clinical trials are also being conducted with ISA247 for the treatment of moderate to severe psoriasis and the prevention of kidney graft rejection.”

-30-

For More Information:

Dr. Randall Yatscoff Stephanie Gillis-Paulgaard

President & CEO Director, Corporate Communications

Isotechnika Inc. Isotechnika Inc.

780-487-1600 (247) 780-909-4661

780-484-4105 (fax) 780-484-4105 (fax)

ryatscoff@isotechnika.com sgillis-paulgaard@isotechnika.com

About Isotechnika

Edmonton-based Isotechnika Inc. is an international biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Isotechnika looks to become the leader in development of immunosuppressant therapies.

Isotechnika's lead drug, ISA247, has successfully completed a Phase 3 Canadian trial for the treatment of moderate to severe psoriasis. ISA247 is currently being investigated in a combined Phase 3 European/Canadian psoriasis trial and a Phase 2b North American trial for the prevention of kidney graft rejection. On
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
4. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. Gentiums Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting
7. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
8. NIEHS Researchers Identify Enzyme Critical in DNA Replication
9. Stanford Researchers Find Brain Pathway of Depression in Rats
10. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
11. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
Post Your Comments:
(Date:7/24/2014)... BUFFALO, N.Y. , July 24, 2014  Kinex ... US FDA for the Company,s KX2-391 Ointment for the ... keratosis. This is the Company,s third IND to be ... months. KX2-391 is a synthetic, orally active ... and tubulin polymerization. KX2-391 promotes the induction of p53, ...
(Date:7/24/2014)... July 24, 2014 Research and Markets ... Monitoring Market by Product, Component, Application and Geography - ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... expected to witness a moderate growth as the markets ... have almost reached the saturation levels. The demand is ...
(Date:7/24/2014)... July 24, 2014 /PRNewswire-iReach/ -- "North America Orthopedic Braces ... data on the North America Orthopedic Braces and Supports ... dollars, and volume (in units) and average price data ... Knee Braces and Supports , Ankle Braces and ... Upper Extremities Braces and Supports. ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5
... Nov. 7, 2011 Inovio Pharmaceuticals, Inc. (NYSE AMEX: ... 30, 2011. Total revenue was $2.6 million and $8.2 ... compared to $1.3 million and $3.8 million for the same periods ... nine months ended September 30, 2011, were $9.0 million and $24.0 ...
... CHICAGO, Nov. 7, 2011 UCB today announced findings ... rates to Cimzia ® (certolizumab pegol) plus methotrexate ... effect on structural joint damage in patients with moderate ... responses were found by both RAPID3 (Routine Assessment of ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 9New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 2New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 3New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 4New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 5New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 6New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 7New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 8New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 9New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 10New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 11New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 12
(Date:7/24/2014)... found a way to delay or even prevent Alzheimer,s ... the anti-aging protein Klotho can prevent neuron death in ... These findings currently appear in the Journal of ... most frequent age-related dementia affecting 5.4 million Americans including ... more than 40 percent of people over the age ...
(Date:7/24/2014)... device or surgical implant is put inside the human ... Guillermo Ameer, most of the time, that response can ... will always get an inflammatory response to some degree," ... School of Engineering and Applied Science and professor of ... with commonly used plastic materials, in particular, is that ...
(Date:7/24/2014)... July 24, 2014 Memantine was initially developed ... marketed in Germany under the brand name Akatinol; it was ... as Ebixa and in the USA to Forest Labs as ... million in 2013. In the US, Forest reported Namenda sales ... expiry in Canada, Australia and the European region has increased ...
(Date:7/24/2014)... is possible to predict long-term cancer risk from a chemical ... The findings, which currently appear in the journal PLOS ... cheaper tests to screen chemicals for their potential cancer causing ... of and mortality from cancer, about 40 percent of Americans ... around 20 percent will die of it. Currently fewer than ...
(Date:7/24/2014)... M.D., director of The Miriam Hospital,s HIV/Viral Hepatitis ... Rhode Island Medical Journal special edition, "RI ... infection (hep c or HCV) is feasible, can ... health challenges, and improve health care disparities. Barriers ... says, include lack of funding earmarked for HCV ...
Breaking Medicine News(10 mins):Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2Health News:Antioxidant biomaterial promotes healing 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Researchers discover new way to determine cancer risk of chemicals 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4
... "In this economy?" That,s the,question Mukti Michael Buck ... and even tripled their income from massage after learning ... reason. CNN recently,reported the field of health and wellness ... growing in this difficult economy. Proud to be a ...
... diagnosis of cancer is devastating at any age, but ... physical, individual and interpersonal development and other often anxiety-provoking ... life, increasingly separating from parents, developing close peer and ... thing like college and jobs. But when confronted with ...
... to help underserved children, the Children,s Health Fund (CHF) ... System, donated by Siemens. Bidding for the state-of-the-art ... million dollars in the first ten days. See ... , http://inr.mediaseed.tv/oneClip_C/?feed=EEHPWrm_uGEQOCdpx2JU_mPv2Er3Cvod The winning bid was made ...
... could get transplants, study finds, , , FRIDAY, Feb. 13 ... an unrelated or unmatched donor can still help children ... anemia, Duke University Medical Center researchers report. , They ... obtain than adult bone marrow, which means more patients ...
... PARAMUS, N.J., Feb. 13 Smart Balance, Inc. (Nasdaq: ... Executive Officer of Smart Balance, Inc., will make a presentation ... in Dana Point, CA, at 2 p.m. EST on Tuesday, ... in length. Only conference attendees will be able to ...
... Feb. 13 Ascension Orthopedics, Inc., a leader ... the Ascension(R) Silicone PIP System at the American ... smallest pre-flexed silicone proximal interphalangeal (PIP) implant offered ... Silicone PIP has an anatomic pre-flexed design reproducing ...
Cached Medicine News:Health News:Double Your Income With Thai Yoga Bodywork? 2Health News:Teens with cancer present unique psychological issues 2Health News:Teens with cancer present unique psychological issues 3Health News:Even Mismatched Cord Blood Can Help Kids 2Health News:Ascension Orthopedics Introduces the Silicone PIP Implant System 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: